Alkermes’ Vivitrol (naltrexone for extended-release injectable suspension) has demonstrated sustained efficacy and safety over 18 months of treatment and supported its clinical ability as a treatment option for opioid dependence following opioid detoxification.
Vivitrol is a once-monthly, extended-release injectable medication, used to treat alcohol dependence and opioid dependence.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
As measured by the number of opioid-free urine screens, Vivitrol, along with psychosocial treatment, reported prolonged efficacy and safety in a one-year, open-label extension of the six-month pivotal study.
The study also measured opioid craving, improvements in quality of life measures, self-reported opioid use and incidence of physical opioid dependence.
National Institute on Drug Abuse (NIDA) has awarded Small Business Innovation Research Program grant for the clinical development programme of Vivitrol.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData
